Evolution of the Average Target: Moderna, Inc.

Evolution of the Target Price: Moderna, Inc.

Changes in Analyst Recommendations: Moderna, Inc.

8f41ac078c1596377b24.02XRYu9zo9vIIAUdDjmAZB8hHqX_U_Z9gyR_m4Atx-Y.kgSZF6sxyuuvGEMrOlH2PHxXe5O4F48L2nsz1MYan4ydP5ArvQXF7ZpnQA~633740effe27d01907b80a7d19088ef4
08/07 Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says MT
08/07 Morgan Stanley Adjusts Price Target Moderna to $39 From $33, Maintains Equalweight Rating MT
07/07 Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says MT
07/07 BofA Adjusts Price Target on Moderna to $38 From $34, Maintains Underperform Rating MT
07/07 RBC Capital Adjusts Moderna Price Target to $45 From $38, Maintains Sector Perform Rating MT
26/06 Piper Sandler Adjusts Price Target on Moderna to $77 From $69, Maintains Overweight Rating MT
26/06 Jefferies Adjusts Price Target on Moderna to $53 From $45, Maintains Hold Rating MT
26/06 Analyst recommendations: Crocs, Dell, On Semiconductor, Qualcomm, Micron… Zonebourse
22/06 Leerink Partners Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating MT
19/06 Oddo BHF Reassured After FDA Decision on Moderna Zonebourse
12/05 MODERNA : Jefferies reiterates its Neutral rating ZD
04/05 Moderna Sees Progress Across Cancer Vaccine, Infectious Disease Pipeline, RBC Says MT
04/05 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
04/05 UBS Adjusts Price Target on Moderna to $45 From $36, Maintains Neutral Rating MT
04/05 RBC Raises Price Target on Moderna to $38 From $35, Keeps Sector Perform Rating MT
01/05 Morgan Stanley Raises Moderna Price Target to $33 From $30 MT
27/04 Goldman Sachs takes stock of several U.S. health-care players Zonebourse
17/04 Goldman Sachs Adjusts Moderna Price Target to $43 From $41, Maintains Neutral Rating MT
15/04 Jefferies Adjusts Price Target on Moderna to $45 From $37, Maintains Hold Rating MT
15/04 Analyst recommendations: Alphabet, Citigroup, Cloudflare, Fair Isaac, Humana… Zonebourse
14/04 Leerink Partners Adjusts Moderna PT to $21 From $12, Maintains Underperform Rating MT
14/04 Analyst recommendations: Biogen, Ford, Ge Vernova, Booking, Comcast… Zonebourse
07/04 RBC Adjusts Price Target on Moderna to $35 From $30, Maintains Sector Perform Rating MT
01/04 Barclays Adjusts Price Target on Moderna to $48 From $25, Maintains Equalweight Rating MT
18/03 Deutsche Bank Adjusts Moderna Price Target to $45 From $28, Maintains Hold Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-29.85%
+23.77%
+21.45%
+47.11%
+13.06%
+11.89%
-4.5%
+30.61%
+3.28%
+21.37%
Average +13.82%
Weighted average by Cap. +17.04%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
68.27USD
Average target price
47.89USD
Spread / Average Target
-29.85%
High Price Target
79.00USD
Spread / Highest target
+15.72%
Low Price Target
22.00USD
Spread / Lowest Target
-67.78%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Morgan Stanley
BofA Securities
RBC Capital Markets
Piper Sandler
Jefferies & Co.
Leerink Partners
JEFFERIES Andrew Tsai
UBS
Goldman Sachs
Barclays
Deutsche Bank Securities
Berenberg Bank
Rothschild & Co Redburn
Bernstein
TD Cowen
Wolfe Research
Evercore ISI
Citigroup
JPMorgan Chase
DBS Bank
Redburn Atlantic
HSBC
Argus
Baptista Research
BERENBERG Harry Gillis
Brookline Capital Markets
Oppenheimer
Oddo BHF
JPMORGAN Jessica Fye
RBC Luca Issi
Redburn
Canaccord Genuity
William Blair & Co.
Guggenheim
SVB Securities LLC
Cowen
Chardan Research
SVB Leerink
Chardan
J.P. Morgan Chase
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
68.27USD
Average target price
47.89USD
Spread / Average Target
-29.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock
  4. Consensus Moderna, Inc.